Latest Revenue Growth News

Vection Technologies reported a 9.6% revenue increase to $36 million and a 25.3% reduction in net loss for FY2025, driven by operational improvements and a key acquisition.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

The Calmer Co. International Limited reported a strong revenue increase of 88% for the year ended June 2025, yet the company still recorded a net loss of nearly $4 million, with no dividends declared.

Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.

PEXA Group delivered a solid FY25 with 16% revenue growth and a 21% rise in EBITDA, while preparing for a UK platform launch backed by NatWest. Despite statutory losses from impairments, the company strengthened its balance sheet and outlined a confident FY26 outlook.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.